Theralase Technologies (TSXV:TLT) ROE % Adjusted to Book Value : -10.46% (As of Sep. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies ROE % Adjusted to Book Value?

Theralase Technologies's ROE % for the quarter that ended in Sep. 2024 was -197.63%. Theralase Technologies's PB Ratio for the quarter that ended in Sep. 2024 was 18.89. Theralase Technologies's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -10.46%.

Theralase Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Theralase Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies ROE % Adjusted to Book Value Chart

Theralase Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-19.69

-11.53

-4.13

-5.61

-8.36

Theralase Technologies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-7.58	-10.24	-14.27	-8.34	-10.46

Competitive Comparison of Theralase Technologies's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Theralase Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's ROE % Adjusted to Book Value falls into.

Theralase Technologies ROE % Adjusted to Book Value Calculation

Theralase Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-182.91%	/	21.88
	=	-8.36%

Theralase Technologies's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-197.63%	/	18.89
	=	-10.46%

Theralase Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

TLTFF:USA TTX:Germany TTX:Germany

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

Executives

Matthew Thomas Perraton	Director
Roger John Dumoulin-white	10% Security Holder, Director, Senior Officer
Kristina Maria Hachey	Senior Officer
Arkady Mandel	Senior Officer
Guy John Anderson	Director
Shawn Shirazi	Senior Officer